Play Video
Neurological Diagnostics Innovation
Amoneta Diagnostics seeks, develops, and qualifies innovative biomarkers for the development of diagnostics in the field of neurological diseases.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
The purpose of Amoneta Diagnostics is to translate new diagnosis methods for various neurodegenerative diseases into products, and to promote the use of these tests in clinical practice.
Our know-how is based on the detection of blood biomarkers.
Currently, our biomarker R&D program is dedicated to the clinical qualification of new biomarkers and diagnostic tools for the diagnosis and the follow-up of Alzheimer’s Disease.
our neurodiagnostic proficiency
key figures
Empowering healthcare professionals as trusted partners, we specialize in neurodegenerative disease diagnostics, providing vital insights to aid in informed medical decision-making.
150
Clients
15
partners
15
YEARS OF EXPERIENCE
10
experts
explore our products
advanced precision medicine tools aiding specialists to make personalized medical decisions, drive progress in disease characterization, and identify potential therapeutic targets.
MemoryLinc®
MemoryLinc® serves as a tracking tool for Alzheimer’s disease progression. By monitoring specific markers, physicians can assess the pathology’s evolution in patients affected by this debilitating condition.
Neurolincs
NeuroLINCs is a panel of blood-based biomarkers specifically designed for early detection of neurological disorders. Its unparalleled accuracy aids in diagnosing conditions such as Parkinson’s disease and multiple sclerosis.
Neurodegene®
NeuroDeGene® offers a comprehensive screening test for neurodegenerative diseases. By combining multiple biomarkers, it provides a holistic assessment of brain health. Early diagnosis and effective management are facilitated through this test.
APO-Easy®
APO-Easy® is a genotyping kit that assesses the genetic risk associated with Alzheimer’s disease. Requiring a small blood sample, this test analyzes the APOE gene genotype, providing essential insights for both patients and healthcare professionals.
LATEST NEWS & Events
14 Feb
Categories Events
Posted on Tags Conference, Neurology
Amoneta Diagnostics announces its participation in the forthcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases in Lisbon.
18 Dec
Categories News
Huningue, France, December 12, 2023Together, Amoneta Diagnostics and the AD Data Initiative announce a collaboration to make data...
06 Nov
Categories News
Posted on Tags Business, Innovation
Amoneta Diagnostics announces that it has become a member of the Pépinière d'entreprises innovantes pH8, the region's premier business incubator focusing on healthcare and new technologies.